s
s
s
Develop highly selective and sensitive PK and ADA assays for rituximab (Rituxan, MabThera) using our range of ready-made anti-idiotypic antibodies.
Table 1. Antibodies Specific to Rituximab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Rituximab Inhibitory Type 1 |
MCA2260 |
MB2 A4 |
Rat IgG2a HRP FITC |
N/A |
PK bridging ELISA Flow cytometry |
|
HCA061 |
AbD02842 |
Fab-dHLX-MH1 HRP |
4.9 |
PK bridging ELISA |
||
HCA062 |
AbD02844 |
Fab-dHLX-MH1 HRP |
10.0 |
PK bridging ELISA |
||
HCA186 |
AbD18423 |
Fab-FH2 |
0.13 |
PK bridging ELISA |
||
HCA201 |
AbD18423_hIgG1 |
hIgG1 |
0.13 |
PK bridging ELISA ADA control |
* Affinity measured in the monovalent Fab format
1 Bivalent Fab antibody, double Helix Loop Helix motif dimerization domain, Myc- and His-6-tags
2 Monovalent Fab antibody DYKDDDDK- and His-6-tags
Type 1 anti-rituximab antibodies inhibit the binding of the drug rituximab to its target, the B cell surface marker CD20. They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug, and for flow cytometry assays. The antibody in fully human IgG1 format is suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
Fig. 1. Rituximab PK bridging ELISA using antibodies HCA186 and MCA2260P.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
Fig. 2. Rituximab ADA bridging ELISA using antibody HCA201.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Ocrelizumab is a second-generation humanized anti-CD20 antibody that binds to an epitope on CD20 that overlaps with the epitope to which rituximab binds (Klein et al. 2013). Rat Anti-Rituximab Antibody, clone MB2A4 (MCA2260) recognises both rituximab and ocrelizumab in a specificity titration ELISA.
Fig. 3. Specificity titration ELISA using MCA2260P.
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.